Skip to main content

Table 2 Duration of fever, incidence of additional treatment, and coronary artery outcomes

From: Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial

  12H group
(n = 19)
24H group
(n = 20)
p value
Duration of fever after treatment initiation, h 21.0 [5–130] 21.5 [3–144] 0.325
Non-responder of initial IVIG, n 7 (36.8) 6 (30.0) 0.741
Total dose of IVIG, g/kg 2 [2–6] 2 [2–6] 0.623
Third-line treatment, n 4 (21.1) 1 (5.0) 0.182
Coronary artery abnormalities, n
 Day 0 1 0 0.487
 Day 7 1 0 0.487
 Day 30 0 0 1.000
  1. Data are median [range], or number (percentage)
  2. IVIG indicates intravenous immunoglobulin
  3. 12H indicates 12 h. 24H indicates 24 h